Interrad Medical’s SecurAcath is Superior to Standard of Care in Newly Published Randomized Controlled Clinical Study
July 16 2024 - 1:00PM
Business Wire
Interrad Medical, Inc., a privately held medical device company,
announces excellent results of a clinical study published in JAMA
Pediatrics titled, “Securement to prevent non-cuffed central venous
catheter dislodgement in pediatrics The SECURED superiority
randomized clinical trial,” Kleidon, et al.
This multi-center, randomized controlled trial was undertaken in
partnership with The Queensland Children’s Hospital, The University
of Queensland, and researchers of the globally respected Alliance
for Vascular Access Teaching and Research (AVATAR), Griffith
University, Brisbane, Australia. The primary purpose was to compare
the dislodgement rate (partial or complete) of non-cuffed CVCs
secured with SecurAcath to the market-leading adhesive securement
device. 307 pediatric patients were randomized, 153 to SecurAcath
and 154 to the adhesive device.
The results showed an impressive 4.4-fold decreased catheter
dislodgement in the SecurAcath group (5.2%) compared to adhesive
device group (22.7%).
Seven secondary outcomes also highly favored SecurAcath as well.
Chief among these, complications reported during catheter dwell
were 39% lower for SecurAcath most notably, central line associated
bloodstream infections (CLABSI) which were 50% lower in the
SecurAcath group.
The study’s comparative cost savings analysis showed that
overall, the SecurAcath device saved AU$36.60 (US$24.54) with every
use.
“Catheter dislodgement is a major clinical problem for our
pediatric patients, with potentially life-threatening consequences.
The results of this study clearly show SecurAcath reduces
dislodgement and saves money, therefore, SecurAcath should be used
preferentially over adhesive device securement,” said Tricia
Kleidon, RN, MNursePrac, lead author of the study publication.
“We are extremely pleased with the very favorable results of
this important comparative study,” said Joe Goldberger, President
and CEO of Interrad Medical, Inc. “This superiority evidence
provides the strongest support to date that SecurAcath will become
the new global standard for catheter securement.”
SecurAcath is the only subcutaneous catheter securement device
in the world. Just one SecurAcath lasts the life of the line and
can significantly reduce the risk of catheter-related infections,
dramatically decrease catheter dislodgement and migration, and
decrease catheter replacement costs resulting in significant cost
savings. SecurAcath has overwhelmingly more positive clinical
evidence and independent clinical guidance than any other catheter
securement device in the world with 27 peer-reviewed scientific
publications consistently concluding clinical and economic
benefits. Learn more at securacath.com
About Interrad Medical, Inc.
Plymouth, Minnesota-based Interrad Medical, Inc. is a developer,
manufacturer and marketer of medical devices designed for
minimally-invasive medical procedures. The lead product, the
SecurAcath Subcutaneous Anchor Securement System (SASS), is a
revolutionary new method for catheter securement that does not
require sutures or adhesives.
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. Any forward-looking statements contained herein are
based on our management's current beliefs and expectations, but are
subject to a number of risks, uncertainties and changes in
circumstances, which may cause actual results or company actions to
differ materially from what is expressed or implied by these
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240716891379/en/
Jeff Killion jeff@securacath.com